title: Tri-Nasal triamcinolone acetonide nasal spray 200 and 400 micrograms qd versus placebo and Nasacort triamcinolone acetonide nasal aerosol 440 micrograms qd in patients suffering from seasonal allergic rhinitis during the grass season.
abstract: Tri-Nasal Nasal Spray is an investigational solution of triamcinolone acetonide (TAA) currently being evaluated as a treatment for allergic rhinitis. The safety and efficacy of 200 and 400 micrograms once daily doses of Tri-Nasal Nasal Spray, an active control (440 micrograms once daily of Nasacort Nasal aerosol), and Tri-Nasal Nasal Spray placebo were compared over a 2-week treatment period in a double-blind (the Nasacort treatment was not blinded), parallel design trial. A total of 377 adult patients in 13 centers were enrolled during the grass pollen season. The primary efficacy variable was the weekly average of the SSI (Symptom Severity Index), the sum of daily nasal congestion, rhinorrhea, and sneezing severity scores from the patient diary. A total of 355 patients completed the study. All active treatments were significantly more effective than placebo in relieving nasal symptoms at each treatment week. The 400 micrograms Tri-Nasal Nasal Spray and Nasacort treatments had a rapid onset of action, demonstrating significant improvement in the SSI versus placebo by the second day of treatment. Results for the individual nasal symptoms and other secondary efficacy measures paralleled those of the primary efficacy variables. Tri-Nasal Nasal Spray and Nasacort were comparable in safety, and in treating the nonocular symptoms of seasonal allergic rhinitis.
authors.affiliation: Laboratory for Applied Immunology, Fairfax, Virginia, USA.
authors.forename: R
authors.initials: R
authors.lastname: Rosenthal
authors.forename: W
authors.initials: W
authors.lastname: Berger
authors.forename: E
authors.initials: E
authors.lastname: Bronsky
authors.forename: R
authors.initials: R
authors.lastname: Dockhorn
authors.forename: P
authors.initials: P
authors.lastname: Korenblat
authors.forename: K
authors.initials: K
authors.lastname: Lampl
authors.forename: W
authors.initials: W
authors.lastname: Lumry
authors.forename: S
authors.initials: S
authors.lastname: Pollard
authors.forename: G
authors.initials: G
authors.lastname: Raphael
authors.forename: C
authors.initials: C
authors.lastname: Rohr
authors.forename: G
authors.initials: G
authors.lastname: Shapiro
authors.forename: M
authors.initials: M
authors.lastname: Valentine
authors.forename: A
authors.initials: A
authors.lastname: Wanderer
authors.forename: L
authors.initials: L
authors.lastname: Fleming
authors.forename: N
authors.initials: N
authors.lastname: LaVallee
authors.forename: M
authors.initials: M
authors.lastname: Stepanians
authors.forename: J
authors.initials: J
authors.lastname: Karafilidis
authors.forename: J
authors.initials: J
authors.lastname: Shilstone
authors.forename: E
authors.initials: E
authors.lastname: Ellis
mesh_terms: D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000336:Aerosols; D000368:Aged; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000503:physiopathology; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000336:Aerosols; D005938:Glucocorticoids; D014222:Triamcinolone Acetonide